Jacobs Levy Equity Management Inc. Sells 99,566 Shares of Inspire Medical Systems, Inc. $INSP

Key Points

• Jacobs Levy Equity Management Inc. sold 99,566 shares of Inspire Medical Systems, reducing its stake by 47.4%, leaving it with 110,594 shares valued at approximately $17.6 million.
• Inspire Medical Systems' stock showed a 0.1% increase and boasts a market capitalization of $2.56 billion, with a 52-week range of $73.92 to $225.00.
• The company recently posted a quarterly earnings report indicating a beat on earnings per share with $0.45, surpassing consensus estimates of $0.22, alongside a revenue increase of 10.8% compared to the prior year.

Jacobs Levy Equity Management Inc. cut its position in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 47.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 110,594 shares of the company's stock after selling 99,566 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.37% of Inspire Medical Systems worth $17,615,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Parallel Advisors LLC lifted its holdings in Inspire Medical Systems by 356.5% in the first quarter. Parallel Advisors LLC now owns 210 shares of the company's stock valued at $33,000 after acquiring an additional 164 shares during the period. Quarry LP raised its holdings in Inspire Medical Systems by 2,127.3% in the 1st quarter. Quarry LP now owns 245 shares of the company's stock valued at $39,000 after acquiring an additional 234 shares during the last quarter. Banque Transatlantique SA purchased a new stake in Inspire Medical Systems in the 1st quarter valued at about $46,000. Smartleaf Asset Management LLC increased its position in Inspire Medical Systems by 27.2% during the first quarter. Smartleaf Asset Management LLC now owns 454 shares of the company's stock worth $71,000 after purchasing an additional 97 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Inspire Medical Systems by 253.7% in the 1st quarter. GAMMA Investing LLC now owns 573 shares of the company's stock worth $91,000 after purchasing an additional 411 shares during the period. 94.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

INSP has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Inspire Medical Systems from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Morgan Stanley decreased their price target on shares of Inspire Medical Systems from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Tuesday, July 15th. Leerink Partners cut their target price on Inspire Medical Systems from $116.00 to $97.00 and set a "market perform" rating on the stock in a research note on Friday, August 15th. Stifel Nicolaus set a $140.00 target price on Inspire Medical Systems and gave the company a "hold" rating in a research note on Tuesday, August 5th. Finally, Evercore ISI started coverage on Inspire Medical Systems in a report on Tuesday, September 2nd. They set an "outperform" rating and a $150.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Inspire Medical Systems has an average rating of "Moderate Buy" and an average price target of $164.50.

Inspire Medical Systems Stock Performance

Inspire Medical Systems stock traded up $3.58 during trading hours on Thursday, hitting $82.35. 541,723 shares of the stock were exchanged, compared to its average volume of 709,684. The business's 50-day moving average is $106.73 and its two-hundred day moving average is $136.36. The stock has a market capitalization of $2.43 billion, a P/E ratio of 47.52, a P/E/G ratio of 2.54 and a beta of 1.15. Inspire Medical Systems, Inc. has a 12 month low of $73.92 and a 12 month high of $218.52.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The firm had revenue of $217.09 million for the quarter, compared to the consensus estimate of $214.50 million. During the same quarter in the prior year, the business earned $0.32 EPS. The business's revenue for the quarter was up 10.8% compared to the same quarter last year. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. On average, equities analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Inspire Medical Systems announced that its Board of Directors has authorized a stock repurchase program on Monday, August 11th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to purchase up to 8.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its shares are undervalued.

Insider Activity

In other news, CFO Richard Buchholz sold 11,000 shares of the business's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the transaction, the chief financial officer directly owned 44,867 shares in the company, valued at $4,190,129.13. The trade was a 19.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.10% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.